Author Contributions: Dr Regine had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Regine, Abrams,
Hoffman, Benson, Macdonald, Willett, Rich.
Acquisition of data: Regine, Winter,
Abrams, Hoffman, Safran.
Analysis and interpretation of data: Regine, Winter, Abrams, Safran, Hoffman, Benson, Macdonald, Kudrimoti,
Drafting of the manuscript: Regine,
Winter, Abrams, Safran, Hoffman, Benson.
Critical revision of the manuscript for important intellectual content: Regine, Winter, Abrams, Safran, Hoffman,
Benson, Konski, Macdonald, Kudrimoti, Fromm, Haddock, Schaefer, Willett,
Statistical analysis: Winter.
Administrative, technical, or material support: Hoffman, Konski, Benson, Kudrimoti, Fromm, Haddock, Schaefer, Willett,
Study supervision: Regine, Abrams,
Safran, Hoffman, Benson, Macdonald, Willett, Rich.
Financial Disclosures: Dr Benson reported receiving funding from Eli Lilly for an advisory and research role.
All funding goes directly to Northwestern University. None of the other authors reported financial disclosures.
Funding/Support: The National Cancer Institute supported the cooperative clinical trials groups, which participated in this study, including the Radiation Therapy Oncology Group (RTOG), the Eastern Cooperative Oncology Group, and the Southwest Oncology group via grants U10 CA21661, U10 CA37422, and U10 CA32115.
Eli Lilly, the makers of gemcitabine, provided financial support to RTOG Headquarters and the statistical center.
Role of the Sponsor: The sponsors of this trial were involved in the design of the study but were not involved in the conduct of the study, collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.